English

Pharmanutra

ESEF

Report (type unavailable) · filed 2026-04-07

Annual consolidated revenue for 2025: about EUR 131.7M, using the latest reported figures. The previous period, 2024, was about EUR 115.5M.

Inspect reported changes Compare with another company Historical disclosures Segments

Watchlist

Latest fiscal year

Revenue

132 million EUR

2025 · EUR

Exact inputs and evidence

Revenue: 131687000 EUR Source

Operating margin

25.98%

2025 · %

Exact inputs and evidence

Operating Income: 34212000 EUR Source
Revenue: 131687000 EUR Source

Operating cash flow

12.1 million EUR

2023 · EUR

Exact inputs and evidence

Operating Cash Flow: 12092000 EUR Source

Free cash flow

-1.16 million EUR

2023 · EUR

Exact inputs and evidence

Operating Cash Flow: 12092000 EUR Source
Capital Expenditure: 13249000 EUR Source

Cash and cash equivalents: 18.6 million EUR 2025-12-31 Source
Exact value

18575000 EUR
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-04-07.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 4 of 11 periods available· newest 2023-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 3 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+14%

Prior period

EUR 115.5 million

2024-01-01 – 2024-12-31
Current period

EUR 131.69 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

131687000 − 115498000 = 16189000 EUR

115498000 EUR · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
131687000 EUR · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Pharmanutra · 2025-12-31 Pharmanutra (esef:815600F8217BC7733697) Year-over-year change in Revenue: 16189000 EUR Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 131687000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6369205 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0 Input fundies:Revenue: 115498000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6369553 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0
The citation records this snapshot. The page link may show a newer release later.
Net income
+20.8%

Prior period

EUR 16.57 million

2024-01-01 – 2024-12-31
Current period

EUR 20.01 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

20014000 − 16572000 = 3442000 EUR

16572000 EUR · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
20014000 EUR · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Pharmanutra · 2025-12-31 Pharmanutra (esef:815600F8217BC7733697) Year-over-year change in Net income: 3442000 EUR Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 20014000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6408165 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0 Input fundies:NetIncome: 16572000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6408543 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-25.2%

Prior period

EUR 4.19 million

2024-01-01 – 2024-12-31
Current period

EUR 3.13 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

3133000 − 4191000 = -1058000 EUR

4191000 EUR · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
3133000 EUR · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Pharmanutra · 2025-12-31 Pharmanutra (esef:815600F8217BC7733697) Year-over-year change in Capital expenditure: -1058000 EUR Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3133000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6547754 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0 Input fundies:CapitalExpenditure: 4191000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6548160 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Operating cash flow.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue EUR 131.69 million 100% of revenue
Operating costs Derived EUR 97.48 million 74% of revenue
Operating income EUR 34.21 million 26% of revenue
Tax, interest and other Derived EUR 14.2 million 11% of revenue
Net income EUR 20.01 million 15% of revenue

Cash

Operating cash flow Unavailable An input is unavailable.
Capital expenditure EUR 3.13 million 2.4% of revenue
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 13%14%74%
2024 14%13%73%
2025 15%11%74%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	56449000	40893000 Derived	15556000	Unavailable	Unavailable	10116000 Derived	Source 2020-01-01 – 2020-12-31: 56449000 EUR Inspect Revenue Open source 2020-01-01 – 2020-12-31: 15556000 EUR Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 11798000 EUR Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1682000 EUR Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	68114000	48034000 Derived	20080000	Unavailable	Unavailable	15426000 Derived	Source 2021-01-01 – 2021-12-31: 68114000 EUR Inspect Revenue Open source 2021-01-01 – 2021-12-31: 20080000 EUR Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 20413000 EUR Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 4987000 EUR Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	82724000	58365000 Derived	24359000	Unavailable	Unavailable	-8691000 Derived	Source 2022-01-01 – 2022-12-31: 82724000 EUR Inspect Revenue Open source 2022-01-01 – 2022-12-31: 24359000 EUR Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 17466000 EUR Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 26157000 EUR Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	100202000	73719000 Derived	26483000	13653000 Derived	12830000	-1157000 Derived	Source 2023-01-01 – 2023-12-31: 100202000 EUR Inspect Revenue Open source 2023-01-01 – 2023-12-31: 26483000 EUR Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 12830000 EUR Inspect Net Income Open source 2023-01-01 – 2023-12-31: 12092000 EUR Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 13249000 EUR Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	115498000	84457000 Derived	31041000	14469000 Derived	16572000	Unavailable	Source 2024-01-01 – 2024-12-31: 115498000 EUR Inspect Revenue Open source 2024-01-01 – 2024-12-31: 31041000 EUR Inspect Operating Income Open source 2024-01-01 – 2024-12-31: 16572000 EUR Inspect Net Income Open source 2024-01-01 – 2024-12-31: 4191000 EUR Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	131687000	97475000 Derived	34212000	14198000 Derived	20014000	Unavailable	Source 2025-01-01 – 2025-12-31: 131687000 EUR Inspect Revenue Open source 2025-01-01 – 2025-12-31: 34212000 EUR Inspect Operating Income Open source 2025-01-01 – 2025-12-31: 20014000 EUR Inspect Net Income Open source 2025-01-01 – 2025-12-31: 3133000 EUR Inspect Capital Expenditure Open source

Amounts are exact, in EUR.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

EUR 131.7M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(EUR)	Source evidence
20202020-12-31	Revenue	56449000	Revenue: 56449000 Open source
20212021-12-31	Revenue	68114000	Revenue: 68114000 Open source
20222022-12-31	Revenue	82724000	Revenue: 82724000 Open source
20232023-12-31	Revenue	100202000	Revenue: 100202000 Open source
20242024-12-31	Revenue	115498000	Revenue: 115498000 Open source
20252025-12-31	Revenue	131687000	Revenue: 131687000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

14% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 56449000 Open source
20212021-12-31	Year over year	20.7%	Revenue: 68114000 Open source Revenue: 56449000 Open source
20222022-12-31	Year over year	21.4%	Revenue: 82724000 Open source Revenue: 68114000 Open source
20232023-12-31	Year over year	21.1%	Revenue: 100202000 Open source Revenue: 82724000 Open source
20242024-12-31	Year over year	15.3%	Revenue: 115498000 Open source Revenue: 100202000 Open source
20252025-12-31	Year over year	14%	Revenue: 131687000 Open source Revenue: 115498000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 26% 2025

Net margin 15.2% 2025

Free cash flow margin -1.2% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	27.6%	Operating Income: 15556000 Open source Revenue: 56449000 Open source
20212021-12-31	Operating margin	29.5%	Operating Income: 20080000 Open source Revenue: 68114000 Open source
20222022-12-31	Operating margin	29.4%	Operating Income: 24359000 Open source Revenue: 82724000 Open source
20232023-12-31	Operating margin	26.4%	Operating Income: 26483000 Open source Revenue: 100202000 Open source
20242024-12-31	Operating margin	26.9%	Operating Income: 31041000 Open source Revenue: 115498000 Open source
20252025-12-31	Operating margin	26%	Operating Income: 34212000 Open source Revenue: 131687000 Open source
2020-12-31	Net margin	Not reported	Revenue: 56449000 Open source
2021-12-31	Net margin	Not reported	Revenue: 68114000 Open source
2022-12-31	Net margin	Not reported	Revenue: 82724000 Open source
20232023-12-31	Net margin	12.8%	Net Income: 12830000 Open source Revenue: 100202000 Open source
20242024-12-31	Net margin	14.3%	Net Income: 16572000 Open source Revenue: 115498000 Open source
20252025-12-31	Net margin	15.2%	Net Income: 20014000 Open source Revenue: 131687000 Open source
20202020-12-31	Free cash flow margin	17.9%	Revenue: 56449000 Open source Operating Cash Flow: 11798000 Open source Capital Expenditure: 1682000 Open source
20212021-12-31	Free cash flow margin	22.6%	Revenue: 68114000 Open source Operating Cash Flow: 20413000 Open source Capital Expenditure: 4987000 Open source
20222022-12-31	Free cash flow margin	-10.5%	Revenue: 82724000 Open source Operating Cash Flow: 17466000 Open source Capital Expenditure: 26157000 Open source
20232023-12-31	Free cash flow margin	-1.2%	Revenue: 100202000 Open source Operating Cash Flow: 12092000 Open source Capital Expenditure: 13249000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 115498000 Open source Capital Expenditure: 4191000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 131687000 Open source Capital Expenditure: 3133000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

EUR 12.1M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(EUR)	Source evidence
20202020-12-31	Operating cash flow	11798000	Operating Cash Flow: 11798000 Open source
20212021-12-31	Operating cash flow	20413000	Operating Cash Flow: 20413000 Open source
20222022-12-31	Operating cash flow	17466000	Operating Cash Flow: 17466000 Open source
20232023-12-31	Operating cash flow	12092000	Operating Cash Flow: 12092000 Open source
20242024-12-31	Operating cash flow	Not reported	No source recorded
20252025-12-31	Operating cash flow	Not reported	No source recorded

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

EUR -1.2M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(EUR)	Source evidence
20202020-12-31	Free cash flow	10116000	Operating Cash Flow: 11798000 Open source Capital Expenditure: 1682000 Open source
20212021-12-31	Free cash flow	15426000	Operating Cash Flow: 20413000 Open source Capital Expenditure: 4987000 Open source
20222022-12-31	Free cash flow	-8691000	Operating Cash Flow: 17466000 Open source Capital Expenditure: 26157000 Open source
20232023-12-31	Free cash flow	-1157000	Operating Cash Flow: 12092000 Open source Capital Expenditure: 13249000 Open source
20242024-12-31	Free cash flow	Unavailable	Capital Expenditure: 4191000 Open source
20252025-12-31	Free cash flow	Unavailable	Capital Expenditure: 3133000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

43.1% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Liabilities / assets	Not reported	Total Assets: 51709000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 71356000 Open source
2022-12-31	Liabilities / assets	Not reported	Total Assets: 100155000 Open source
20232023-12-31	Liabilities / assets	51.6%	Total Liabilities: 58036000 Open source Total Assets: 112443000 Open source
20242024-12-31	Liabilities / assets	47.1%	Total Liabilities: 55273000 Open source Total Assets: 117408000 Open source
20252025-12-31	Liabilities / assets	43.1%	Total Liabilities: 53992000 Open source Total Assets: 125233000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.35× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	3.63×	Current Assets: 40406000 Open source Current Liabilities: 11144000 Open source
20212021-12-31	Current assets / current liabilities	3.31×	Current Assets: 55519000 Open source Current Liabilities: 16748000 Open source
20222022-12-31	Current assets / current liabilities	2.28×	Current Assets: 58727000 Open source Current Liabilities: 25790000 Open source
20232023-12-31	Current assets / current liabilities	2.12×	Current Assets: 58682000 Open source Current Liabilities: 27648000 Open source
20242024-12-31	Current assets / current liabilities	2.38×	Current Assets: 65006000 Open source Current Liabilities: 27340000 Open source
20252025-12-31	Current assets / current liabilities	2.35×	Current Assets: 72902000 Open source Current Liabilities: 31033000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	EUR 11.8 million Exact value Exact value: 11798000 EUR 2020-01-01 – 2020-12-31: 11798000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharmanutra · 2020-12-31 Pharmanutra (esef:815600F8217BC7733697) Operating Cash Flow: 11798000 EUR Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: 11798000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2021-12-31/ESEF/IT/0/815600F8217BC7733697-2021-12-31.zip#14541456 Filing: 815600F8217BC7733697-2021-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	EUR 1.68 million Exact value Exact value: 1682000 EUR 2020-01-01 – 2020-12-31: 1682000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharmanutra · 2020-12-31 Pharmanutra (esef:815600F8217BC7733697) Capital Expenditure: 1682000 EUR Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 1682000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2021-12-31/ESEF/IT/0/815600F8217BC7733697-2021-12-31.zip#14542947 Filing: 815600F8217BC7733697-2021-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	EUR 10.12 million Calculation and evidence 11798000 − 1682000 EUR Exact free cash flow: 10116000 EUR 2020-01-01 – 2020-12-31: 11798000 EUR · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1682000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharmanutra · 2020-12-31 Pharmanutra (esef:815600F8217BC7733697) Free cash flow: 10116000 EUR Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 11798000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2021-12-31/ESEF/IT/0/815600F8217BC7733697-2021-12-31.zip#14541456 Filing: 815600F8217BC7733697-2021-12-31-ESEF-IT-0 Input fundies:CapitalExpenditure: 1682000 EUR (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2021-12-31/ESEF/IT/0/815600F8217BC7733697-2021-12-31.zip#14542947 Filing: 815600F8217BC7733697-2021-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	EUR 20.41 million Exact value Exact value: 20413000 EUR 2021-01-01 – 2021-12-31: 20413000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharmanutra · 2021-12-31 Pharmanutra (esef:815600F8217BC7733697) Operating Cash Flow: 20413000 EUR Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: 20413000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2021-12-31/ESEF/IT/0/815600F8217BC7733697-2021-12-31.zip#14540857 Filing: 815600F8217BC7733697-2021-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	EUR 4.99 million Exact value Exact value: 4987000 EUR 2021-01-01 – 2021-12-31: 4987000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharmanutra · 2021-12-31 Pharmanutra (esef:815600F8217BC7733697) Capital Expenditure: 4987000 EUR Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 4987000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2021-12-31/ESEF/IT/0/815600F8217BC7733697-2021-12-31.zip#14542479 Filing: 815600F8217BC7733697-2021-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	EUR 15.43 million Calculation and evidence 20413000 − 4987000 EUR Exact free cash flow: 15426000 EUR 2021-01-01 – 2021-12-31: 20413000 EUR · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 4987000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharmanutra · 2021-12-31 Pharmanutra (esef:815600F8217BC7733697) Free cash flow: 15426000 EUR Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 20413000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2021-12-31/ESEF/IT/0/815600F8217BC7733697-2021-12-31.zip#14540857 Filing: 815600F8217BC7733697-2021-12-31-ESEF-IT-0 Input fundies:CapitalExpenditure: 4987000 EUR (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2021-12-31/ESEF/IT/0/815600F8217BC7733697-2021-12-31.zip#14542479 Filing: 815600F8217BC7733697-2021-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	Unavailable Not reported for this period.	EUR 17.47 million Exact value Exact value: 17466000 EUR 2022-01-01 – 2022-12-31: 17466000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharmanutra · 2022-12-31 Pharmanutra (esef:815600F8217BC7733697) Operating Cash Flow: 17466000 EUR Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: 17466000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2023-12-31/ESEF/IT/0/815600F8217BC7733697-2023-12-31.zip#5986447 Filing: 815600F8217BC7733697-2023-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	EUR 26.16 million Exact value Exact value: 26157000 EUR 2022-01-01 – 2022-12-31: 26157000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharmanutra · 2022-12-31 Pharmanutra (esef:815600F8217BC7733697) Capital Expenditure: 26157000 EUR Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 26157000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2023-12-31/ESEF/IT/0/815600F8217BC7733697-2023-12-31.zip#5987670 Filing: 815600F8217BC7733697-2023-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 8.69 million Calculation and evidence 17466000 − 26157000 EUR Exact free cash flow: -8691000 EUR 2022-01-01 – 2022-12-31: 17466000 EUR · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 26157000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharmanutra · 2022-12-31 Pharmanutra (esef:815600F8217BC7733697) Free cash flow: -8691000 EUR Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 17466000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2023-12-31/ESEF/IT/0/815600F8217BC7733697-2023-12-31.zip#5986447 Filing: 815600F8217BC7733697-2023-12-31-ESEF-IT-0 Input fundies:CapitalExpenditure: 26157000 EUR (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2023-12-31/ESEF/IT/0/815600F8217BC7733697-2023-12-31.zip#5987670 Filing: 815600F8217BC7733697-2023-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	EUR 12.83 million Exact value Exact value: 12830000 EUR 2023-01-01 – 2023-12-31: 12830000 EUR Inspect Net Income Open source Share or cite Citation for Net Income · Pharmanutra · 2023-12-31 Pharmanutra (esef:815600F8217BC7733697) Net Income: 12830000 EUR Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=EUR&dimensions= Input fundies:NetIncome: 12830000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2024-12-31/ESEF/IT/0/815600F8217BC7733697-2024-12-31.zip#6937222 Filing: 815600F8217BC7733697-2024-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	EUR 12.09 million Exact value Exact value: 12092000 EUR 2023-01-01 – 2023-12-31: 12092000 EUR Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharmanutra · 2023-12-31 Pharmanutra (esef:815600F8217BC7733697) Operating Cash Flow: 12092000 EUR Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=EUR&dimensions= Input fundies:OperatingCashFlow: 12092000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2023-12-31/ESEF/IT/0/815600F8217BC7733697-2023-12-31.zip#5986045 Filing: 815600F8217BC7733697-2023-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	EUR 13.25 million Exact value Exact value: 13249000 EUR 2023-01-01 – 2023-12-31: 13249000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharmanutra · 2023-12-31 Pharmanutra (esef:815600F8217BC7733697) Capital Expenditure: 13249000 EUR Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 13249000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2024-12-31/ESEF/IT/0/815600F8217BC7733697-2024-12-31.zip#7062504 Filing: 815600F8217BC7733697-2024-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	−EUR 1.16 million Calculation and evidence 12092000 − 13249000 EUR Exact free cash flow: -1157000 EUR 2023-01-01 – 2023-12-31: 12092000 EUR · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 13249000 EUR · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharmanutra · 2023-12-31 Pharmanutra (esef:815600F8217BC7733697) Free cash flow: -1157000 EUR Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 12092000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2023-12-31/ESEF/IT/0/815600F8217BC7733697-2023-12-31.zip#5986045 Filing: 815600F8217BC7733697-2023-12-31-ESEF-IT-0 Input fundies:CapitalExpenditure: 13249000 EUR (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2024-12-31/ESEF/IT/0/815600F8217BC7733697-2024-12-31.zip#7062504 Filing: 815600F8217BC7733697-2024-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	EUR 16.57 million Exact value Exact value: 16572000 EUR 2024-01-01 – 2024-12-31: 16572000 EUR Inspect Net Income Open source Share or cite Citation for Net Income · Pharmanutra · 2024-12-31 Pharmanutra (esef:815600F8217BC7733697) Net Income: 16572000 EUR Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=EUR&dimensions= Input fundies:NetIncome: 16572000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6408543 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	EUR 4.19 million Exact value Exact value: 4191000 EUR 2024-01-01 – 2024-12-31: 4191000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharmanutra · 2024-12-31 Pharmanutra (esef:815600F8217BC7733697) Capital Expenditure: 4191000 EUR Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 4191000 EUR (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6548160 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.
2025 2025-01-01 – 2025-12-31	EUR 20.01 million Exact value Exact value: 20014000 EUR 2025-01-01 – 2025-12-31: 20014000 EUR Inspect Net Income Open source Share or cite Citation for Net Income · Pharmanutra · 2025-12-31 Pharmanutra (esef:815600F8217BC7733697) Net Income: 20014000 EUR Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=EUR&dimensions= Input fundies:NetIncome: 20014000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6408165 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	EUR 3.13 million Exact value Exact value: 3133000 EUR 2025-01-01 – 2025-12-31: 3133000 EUR Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharmanutra · 2025-12-31 Pharmanutra (esef:815600F8217BC7733697) Capital Expenditure: 3133000 EUR Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:25:08Z Snapshot: 53fb962f27450dca6d5dcc9f2d7b64d1d80e2657759c3af7ff48fdacd8df8056 Dimensions: Consolidated View: https://fundies.io/companies/esef/815600F8217BC7733697/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=EUR&dimensions= Input fundies:CapitalExpenditure: 3133000 EUR (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/815600F8217BC7733697/2025-12-31/ESEF/IT/0/815600F8217BC7733697-2025-12-31.zip#6547754 Filing: 815600F8217BC7733697-2025-12-31-ESEF-IT-0 The citation records this snapshot. The page link may show a newer release later.	Unavailable Free cash flow cannot be calculated because Operating cash flow is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

5 filings · 354 latest values · 354 originally reported values

Dataset published 2026-11-09. Source filing dates and reporting periods are shown separately.

Identifiers: 815600F8217BC7733697, esef:815600F8217BC7733697

Pharmanutra

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation